Category Archive : Bitcoin Gold

Bitcoin (BTC) Drops As Crypto Sentiment Hits ‘Rock Bottom’

Bitcoin and Ethereum lost ground at press time on Monday evening, as both coins failed to breach their key levels amid diminishing returns, with the global cryptocurrency market cap falling 3% to $1.25 trillion.

Price Performance Of Major Coins
Bitcoin BTC/USD-3.7%-2.4%$29,169.44
Ethereum ETH/USD-3.2%-2.5%$1,977.84
Dogecoin DOGE/USD-3%5.5%$0.08

Top 24-Hour Gainers (Data via CoinMarketCap)
Cryptocurrency24-Hour % Change (+/-)Price
Bitcoin Gold (BTG)+25%$24.37
TerraUSD (UST)+11.8%$0.0715
Stacks (STX)+9.4%​​$0.61

See Also: Best USDC Interest Rates

What Happened: While U.S. stocks rallied on Monday, the momentum fizzled out after the…


Twinvictus Bomber Blazers™ Italian fabric jackets offer all you need for business & casual » Gadget Flow

Get the best of both business and casual worlds when you don the Twinvictus Bomber Blazers™ Italian fabric jackets. This collection gives you everything you want from a stylish bomber jacket in a design that doubles as a blazer. With styles you’ll wear all day long, they use high-quality Italian fabrics like 100% Merino wool, pure virgin wool, silk, and pure coconut for comfortability and class. With a Dutch design, the Bomber Blazer comes in several styles. Choose from Navy x Camouflage, Camel x Paisley, Navy Pinstripe x Emblems, Blue Camouflage x Bitcoin Gold. Ensuring you always feel dressed for success, this lightweight jacket resists odors, wicks moisture, regulates temperature, and offers incredible breathability. From business to casual and casual to chic, this versatile jacket has a high-quality, sophisticated design.


Bitcoin Gold Leads Crypto Market Recovery With 40% Gain

Smaller cryptocurrencies surged Monday as bitcoin saw a relief rally, tracking signs of risk reset in traditional markets.

Leading the market higher at 9.38 am ET was bitcoin gold, a cryptocurrency created via a hard fork of bitcoin in mid-November 2017. The 4-1/2-year-old cryptocurrency changed hands at $27, representing a 40% gain on a 24-hour basis. Prices reached $32 during the early US hours, hitting the highest since May 11, Forbes data shows.

While the exact catalyst for the outsized gain is unknown, the move has come on the back of solid volumes. Chart analysts consider low volume rallies as bull traps powered by fumes and just a few traders.

The daily bitcoin gold-tether (BTG-USDT) volume bar on Binance, the dominant crypto…


What’s Next for Very Bullish Rated Bitcoin Gold (BTG)?

Bitcoin Gold (BTG) gets a very bullish rating from InvestorsObserver Monday. The Digital Money asset is up 19.8% to $22.86 while the broader crypto market is up 1.25%.

Bitcoin Gold has a Very Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on Bitcoin Gold!

Very Bullish

Over the last five days, Bitcoin Gold has earned a Very Bullish rating on the InvestorsObserver Sentiment Score. The Sentiment Score measures the performance of Bitcoin Gold over the past five days by volume and price movement.

The Sentiment Score provides a quick, short-term look at the crypto’s recent performance. This can be useful for both short-term investors looking to ride a rally and longer-term investors trying to buy the dip.

Price Levels

Bitcoin Gold is currently trading at a five-day high. The…


Metastatic Bones Cancer Medication Treatment Market would Register a Healthy Growth of USD 49.93 billion by 2027 :Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic

New Jersey, United States,- The latest report published by MR Accuracy Reports indicates that the Metastatic Bones Cancer Medication Treatment Market is likely to accelerate strongly in the coming years. Analysts have studied market drivers, restraints, risks, and opportunities in the global market. The Metastatic Bones Cancer Medication Treatment Market report shows the likely direction of the market in the coming years along with its estimates. An accurate study aims to understand the market price. By analyzing the competitive landscape, the authors of the report have made excellent efforts to help readers understand the key business tactics that major companies are using to maintain market sustainability.

Key Players Mentioned in the Metastatic Bones Cancer Medication Treatment Market Research Report: Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company,…


B2Gold Corp. (NYSEAMERICAN:BTG) Receives Consensus Rating of “Buy” from Analysts

Shares of B2Gold Corp. (NYSEAMERICAN:BTG – Get Rating) (TSE:BTO) have earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $7.28.

A number of research firms have recently commented on BTG. Scotiabank increased their price objective on B2Gold from C$8.00 to C$8.25 in a report on Tuesday, April 19th. Canaccord Genuity Group decreased their price objective on B2Gold from C$8.50 to C$8.00 in a research report on Thursday, January 27th. National Bank Financial increased their price objective on B2Gold from C$7.75 to C$8.50…


Metastatic Bones Cancer Market 2022 Segments Analysis by Top Key Players :Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic

The Metastatic Bones Cancer report is an in-depth examination of the global Metastatic Bones Cancer’s general consumption structure, development trends, sales techniques, and top nations’ sales. The research looks at well-known providers in the global Metastatic Bones Cancer industry, as well as market segmentation, competition, and the macroeconomic climate. A complete Metastatic Bones Cancer analysis takes into account a number of aspects, including a country’s population and business cycles, as well as market-specific microeconomic consequences. The global market research also includes a specific competition landscape section to help you better understand the Metastatic Bones Cancer industry. This information can help stakeholders make educated decisions before investing.

Leading players of Metastatic Bones Cancer including:

Amgen, Merck & Co, Roche,…


B2Gold: A Steady Dividend Payer At A Very Reasonable Price (NYSE:BTG)

The Q1 Earnings Season for the Gold Miners Index (GDX) is nearly complete, and one of the first companies to report its results was B2Gold (NYSE:BTG). Overall, the company had a solid start to the year, reporting higher than budgeted production at all its operations and operating costs well below estimates. This suggests we could see minimal margin compression this year despite inflationary pressures, assuming the gold price average can average $1,900/oz. Given B2Gold’s nearly unparalleled consistency in over-delivering and its attractive dividend yield, I would view pullbacks below $3.80 as low-risk buying opportunities.

Otjikoto Operations (Company Website)

B2Gold released its Q1 results earlier this month, reporting quarterly gold production of ~196,500 ounces from its operations and ~209,400 ounces when including contribution from its interest in Calibre Mining (OTCQX:CXBMF)….


B2Gold Corp. (NYSE:BTG) Expected to Post Earnings of $0.06 Per Share

Wall Street analysts predict that B2Gold Corp. (NYSE:BTG – Get Rating) will post earnings of $0.06 per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for B2Gold’s earnings. The lowest EPS estimate is $0.05 and the highest is $0.06. B2Gold posted earnings of $0.04 per share during the same quarter last year, which suggests a positive year over year growth rate of 50%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that B2Gold will report full year earnings of $0.38 per share for the current financial year, with EPS estimates ranging from $0.33 to $0.43. For the next fiscal year, analysts anticipate that the company will report earnings of $0.43 per share, with EPS estimates ranging from $0.39 to $0.49. Zacks’ EPS calculations…


‘Back to where he never left’: founder of Brazil’s BTG Pactual returns to fold

A self-made billionaire by the age of 40 and the face of an institution once described as the “Goldman of the Tropics”, at one time André Esteves was the wunderkind of Latin American finance.

Then the Brazilian suffered a dramatic fall. Arrested in connection with a sprawling political corruption scandal, in November 2015 he resigned as chair and chief executive of the investment bank he founded, plunging it into turmoil.

Almost four years after his name was cleared, Esteves has returned to the board of BTG Pactual. He is, as the company’s acronym reputedly spells out, now officially ‘back to the game’.

Shareholders approved him as chair of the $22bn-valued group at the end of April. On paper it was the final step in a long journey by one of Brazil’s highest-profile business figures to restore his commanding position.

But in reality, the elevation merely bestowed a…